Old Web
English
Sign In
Acemap
>
authorDetail
>
Diana Lindquist
Diana Lindquist
Rutgers University
Pharmacokinetics
Medicine
Pharmacology
Carboplatin
Immunology
5
Papers
145
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors
2019
Investigational New Drugs
Mark N. Stein
Susan Goodin
Murugeson Gounder
Darlene Gibbon
Rebecca A. Moss
Daniella E. Portal
Diana Lindquist
Yujie Zhao
Naoko Takebe
Antoinette R. Tan
Joseph Aisner
Hongxia Lin
Neal Ready
Janice M. Mehnert
Show All
Source
Cite
Save
Citations (6)
CTEP #8342 autophagy modulation with antiangiogenic therapy: A phase I trial of sunitinib (Su) and hydroxychloroquine (HCQ).
2017
Journal of Clinical Oncology
Nataliya Melnyk
Xiaoqi Xie
Danny Ju Yong Koh
Megha Rajpal
Rebecca A. Moss
Darlene Gibbon
James M. Cleary
Minh-Thu Tran
Pamela Scott
Mark N. Stein
Antoinette R. Tan
Shari Adams
Diana Lindquist
Pamela Jo Harris
Naoko Takebe
Hongxia Lin
Joseph Aisner
Eileen White
Robert S. DiPaola
Janice M. Mehnert
Show All
Source
Cite
Save
Citations (1)
Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.
2013
Cancer Chemotherapy and Pharmacology
Antoinette R. Tan
Darlene Gibbon
Mark N. Stein
Diana Lindquist
Jeffery W. Edenfield
Julie C. Martin
Charles Gregory
A. Benjamin Suttle
Hiroomi Tada
Jeffrey Botbyl
Joseph J. Stephenson
Show All
Source
Cite
Save
Citations (72)
Phase I Study of Pazopanib in Combination with Paclitaxel and Carboplatin Given Every 21 Days in Patients with Advanced Solid Tumors
2012
Molecular Cancer Therapeutics
Howard A. Burris
Afshin Dowlati
Rebecca A. Moss
Jeffrey R. Infante
Suzanne F. Jones
David R. Spigel
Kelly Levinson
Diana Lindquist
Shelby D. Gainer
Mohammed M. Dar
A. Benjamin Suttle
Howard A. Ball
Antoinette R. Tan
Show All
Source
Cite
Save
Citations (35)
Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors.
2011
Journal of Clinical Oncology
Antoinette R. Tan
Deborah Toppmeyer
Mark N. Stein
Rebecca A. Moss
Murugesan Gounder
Diana Lindquist
Jiuping Ji
Alice P. Chen
Merrill J. Egorin
Brian F. Kiesel
Jan H. Beumer
Robert S. DiPaola
Show All
Source
Cite
Save
Citations (31)
1